Inovio (INO) announced that the FDA has notified the company that it agrees with its rolling submission timeline for the BLA for INO-3107 as a treatment for adults with Recurrent Respiratory Papillomatosis. Inovio anticipates completing its submission to the FDA in the coming months and requesting priority review, with the goal of file acceptance by the FDA by the end of 2025.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INO:
- Inovio Pharmaceuticals: Hold Rating Amid Financial Challenges and Competitive Pressures
- Inovio Pharmaceuticals Reports Q2 2025 Financial Progress
- Inovio reports Q2 EPS (61c), consensus (62c)
- Options Volatility and Implied Earnings Moves Today, August 12, 2025
- Inovio announces peer-reviewed data from INO-3107 study